Canada's misguided changes to drug regulation could fast-track unproven medications and divert funds from other health needs

By Steven G. Morgan, Professor, School of Population and Public Health, University of British Columbia
Aidan Hollis, Professor of Economics, University of Calgary
Christopher McCabe, Professor of Health Economics, Queen's University Belfast
Matthew Herder, Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
Mike Paulden, Associate professor, School of Public Health, University of Alberta

The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.

Read complete article

~	HIV in South Africa: why rolling out a groundbreaking new shot will miss a critical group of men

~	Poop tests and blood tests join colonoscopy as options for colorectal cancer screening

~	Who is talking about artificial intelligence in Ecuador?

~	Chinese American teens experience depression, anxiety at higher rates than peers – here’s why their parents may miss the warning signs

~	I’ve been studying racist costume parties for a decade, and colleges are failing at educating the students about why they’re wrong

~	Scientists used a method from ecology to identify whether icy moons could hold conditions for life

~	PFAS leave fingerprints in your blood – researchers are figuring out how forever chemicals transform in your body to read these clues

~	Far removed from today’s global juggernaut, soccer was born in the well-heeled boarding schools of 19th-century England

~	Better patient-nurse relationships can transform mental health care – and make hospital stays shorter

~	Why Africa – and the world – remain dangerously unprepared for the next pandemic